Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy
Article in FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology (November 2023)